VRDN: Rounding Bottom detected on 11 Aug 2026

VRDN is forming a rounding bottom pattern with a current price of $23.06, trading 32.75% below its 52-week high but 74.96% above its 52-week low. The pattern structure scores 13.0/15, volume confirms at 10.0/12, and breakout momentum rates 12.0/13, yielding an overall score of 73/98—solid but not exceptional. Key support sits at $13.18, resistance at $28.68, with a conservative target of $24.06. The stock has rallied 19.42% in one week and 38.83% over three months. RSI stands at 71.01 (overbought), MACD histogram positive at 0.3236, and volume ratio elevated at 1.22x average. Low beta of 0.72 suggests defensive characteristics within the health-care sector.

Viridian just launched its first commercial drug, Lumvoa, with early indications showing strong physician and patient feedback plus positive payer engagement. The company reported $982 million in cash and equivalents as of June 30, 2026, following a successful $394 million convertible debt and equity financing in May 2026. The FDA granted a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED), with the European MAA accepted for review in February 2026. However, analyst consensus forecasts 2026 revenues of $21.6 million (70% decline) with losses projected at $4.04 per share, a 27% increase versus prior forecasts. The pipeline includes VRDN-008 phase 1 data on track for 2H 2026 and VRDN-006 development plans expected in 2026.

A successful rounding bottom breakout would confirm on a close above $28.68 with volume above 1.86 million shares (1.2x average) to validate the pattern. Historical data suggests a measured move target of $24.06 (conservative)—representing a modest 4.3% advance from current levels, implying the pattern is already near resolution. The 64.72% win probability indicates better-than-random odds but not high conviction. Invalidation occurs decisively below $13.18 support, which would signal pattern failure and suggest a deeper pullback to test the broader rounding structure.

Multiple risks warrant caution. RSI at 71.01 signals overbought conditions, creating mean-reversion risk. Analyst consensus recently cut 2026 revenue guidance by 19% to $21.6 million and raised loss forecasts by 5% to $4.04 per share, indicating execution headwinds with the Lumvoa launch. Analyst price targets span $22.00 to $50.00, a 127% range reflecting high uncertainty on commercial success and development timelines. The company remains unprofitable with no guarantee early-stage pipeline assets (VRDN-006, VRDN-008) will advance successfully. Biotech sector volatility is structurally elevated; while VRDN's beta of 0.72 is defensive, clinical trial results or regulatory setbacks can trigger sharp repricing regardless of technicals.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.